Takeda Pharmaceutical Co Ltd ADR (TAK) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US8740602052
Takeda Pharmaceutical Co Ltd ADR financials
| Fiscal year | 2025 | 2026 |
|---|---|---|
| Revenue | 30.10 bn USD | 29.99 bn USD |
| Gross profit | 19.72 bn USD | 15.32 bn USD |
| Operating income | 2.25 bn USD | – |
| EBIT | 2.25 bn USD | 3.60 bn USD |
| Net income | 709.14 m USD | 1.28 bn USD |
| Diluted EPS – continuing operations | 0.22 USD | 0.40 USD |
Full history since 2000, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Takeda Pharmaceutical Co Ltd ADR
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Takhzyro, Advate, Elaprase, Replagal, Vpriv, Adynovate/Adynovi, Livtencity, ADZYNMA, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Flexbumin, Adcetris, Leuplin/Enantone, Ninlaro, Iclusig, FRUZAQLA, Alunbrig, vyvanse/elvanse, Trintellix, and QDENGA brands. It has licensing and collaboration for the development and commercialization of products with Arrowhead Pharmaceuticals, Cour Pharmaceuticals, Engitix, Halozyme, Mirum Pharmaceuticals, Ucsd/Fortis Advisors, Zedira/Dr. Falk Pharma, Ac Immune, Acurastem, Anima Biotech, Biomarin, Denali Therapeutics, Luxna Biotech, Neurocrine Biosciences, Peptidream, Abbvie, Adimab, Ascentage Pharma, Crescendo Biologics, Exelixis, F-Star, Gsk, Heidelberg Pharma, Innovent Biologics, Keros Therapeutics, Kumquat Biosciences, Protagonist Therapeutics, Halozyme, Kamada, Johnson & Johnson/Momenta Pharmaceuticals, Previpharma, Novavax, Bridgene Biosciences, Charles River Laboratories, Iambic Therapeutics, Ipsen, Km Biologics, Massachusetts Institute Of Technology, and Nabla Bio. The company operates in Japan, the United States. Europe, Canada, Latin America, China, Asia, Russia/Commonwealth of Independent States, the Middle East, Oceania, and Africa. The company was founded in 1781 and is headquartered in Chuo, Japan.
More stocks
- Panasonic Holdings Corporation (PCRHY)
- CSL Ltd (CSL.AX)
- Keysight Technologies (KEYS)
- Wesfarmers Ltd (WES.AX)
- Occidental Petroleum (OXY)
- TransDigm Group (TDG)
- Anglo American PLC (AAL.L)
- TE Connectivity (TEL)
- Sea Ltd (SE)
- Arthur J. Gallagher & Co. (AJG)
- Takeda Pharmaceutical Co Ltd (4502.T)
- Monolithic Power Systems (MPWR)
Not investment advice. All data without warranty, price as of 14.10.2026. Details in the risk notice.